Asthma Seretide is indicated in the regular treatment of asthma where use of a combination product (long- acting β 2 agonist and inhaled corticosteroid) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β 2 agonist or - patients already adequately controlled on both inhaled corticosteroid and long-acting β 2 agonist Note: Seretide 50 microgram /100 microgram strength is not appropriate in adults and children with severe asthma. Chronic Obstructive Pulmonary Disease (COPD) Seretide (50 micrograms salmeterol and 500 micrograms fluticasone propionate) is indicated for the symptomatic treatment of patients with COPD, with a FEV 1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
Novartis has presented new data that demonstrated once-daily Ultibro Breezhaler (indacaterol/glycopyrronium bromide) was superior in reducing exacerbations (flare ups) and...
Salmeterol is a selective β 2 -agonist indicated for reversible airways obstruction in patients with asthma and chronic obstructive pulmonary disease (COPD). In asthma (including nocturnal asthma and exercise induced symptoms) it is indicated for those treated with inhaled corticosteroids who require a long-acting beta agonist in accordance with current treatment guidelines. Serevent Accuhaler is not a replacement for inhaled or oral corticosteroids which should be continued at the same dose, and not stopped or reduced, when treatment with Serevent Accuhaler is initiated.
GlaxoSmithKline and Innoviva announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta...
Sandoz, has received Danish marketing authorisation for AirFluSal Forspiro (formerly known as VR315), an innovative new inhaler for patients with...
Further analyses of Novartis' head-to-head FLAME study suggest that inhaled corticosteroids (ICS) may not be needed in some chronic obstructive...
Novartis announced top-line results from the Phase IV INSTEAD switch study in patients with Chronic Obstructive Pulmonary Disease (COPD), which...
Novartis announced positive results from the FLASH study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease...
Ventolin Accuhaler is indicated in adults, adolescents and children aged 4 to 11 years. Ventolin Accuhaler can be used in the management of asthma, bronchospasm and/or reversible airways obstruction. Ventolin Accuhaler is particularly suitable for the relief of asthma symptoms. It should be used to relieve symptoms when they occur, and to prevent them in those circumstances recognised by the patient to precipitate an asthma attack (e.g. before exercise or unavoidable allergen exposure).
Fluticasone propionate given by inhalation offers preventative treatment for asthma. At recommended doses it has a potent glucocorticoid anti-inflammatory action within the lungs, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. Adults: Prophylactic management in: Mild asthma: Patients requiring intermittent symptomatic bronchodilator asthma medication on a regular daily basis. Moderate asthma: Patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone. Severe asthma: Patients with severe chronic asthma and those who are dependent on systemic corticosteroids for adequate control of symptoms. On introduction of inhaled fluticasone propionate many of these patients may be able to reduce significantly, or to eliminate, their requirement for oral corticosteroids. Children: Any child who requires prophylactic medication for asthma, including patients not controlled on currently available prophylactic medication.